Sling Therapeutics has closed a significant $123 million Series C financing round, directing the capital toward the pivotal late-stage clinical…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
A new class of compounds shows promising antibacterial properties, with the potential to aid the fight against antimicrobial resistance.
In a significant development in the global battle against antimicrobial resistance (AMR), an international research collaboration spearheaded by scientists at…
Read More
Tirzepatide Confirmed as Best-in-Class Obesity Therapy Following Landmark SURMOUNT-MAINTAIN Trial Results
Findings from the pivotal Phase III SURMOUNT-MAINTAIN trial, presented at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye,…
Read More
Corcept’s first-in-class ovarian cancer drug gains FDA approval – Pharmaceutical Technology
Corcept Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its selective…
Read More
